June 6, 2019 / 8:32 AM / 11 days ago

BUZZ-Motif Bio: Plunges as lead drug trips on FDA hurdle

** Biopharma Motif Bio Plc’s shares down 45% at 4.5 pence - stock at record low - worst pct loser on LSE

** U.S. drug regulator FDA indicates that additional trial required for co’s lead product iclaprim’s marketing approval

** FDA concerned about potential liver toxicity of the drug

** Iclaprim’s drug application was for treating acute bacterial skin, skin structure infections

** Co can operate only for 3 more months with available cash of $2.3 mln; debt at $7.1 mln

** Co looking to raise capital; evaluating options for further funding strategy (Reporting by Sangameswaran S in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below